Atypical hemolytic uremic syndrome
ay-TIP-i-kuhl HEE-muh-lit-ik yoo-REE-mik SIN-drohm
Also known as: aHUS, non-diarrheal HUS
At a Glance
What is Atypical hemolytic uremic syndrome?
Atypical hemolytic uremic syndrome (aHUS) is a rare disease that primarily affects the kidneys and blood. It is caused by abnormal activation of the immune system, leading to the destruction of red blood cells. Over time, this can cause kidney failure and damage to other organs. Early symptoms often include fatigue, pale skin, and decreased urine output. As the disease progresses, it can lead to high blood pressure, swelling, and more severe kidney problems. Early diagnosis is crucial to prevent irreversible organ damage and improve outcomes. The condition can significantly impact family life due to the need for ongoing medical care and potential for serious health complications. Prognosis varies, but with treatment, many individuals can manage symptoms and maintain a good quality of life. Daily life may involve regular medical appointments, medication, and dietary adjustments. Genetic counseling may be recommended for affected families. Support from healthcare providers and patient communities can be invaluable. Awareness and education about the condition are essential for early intervention and management.
Medical Definition
Atypical hemolytic uremic syndrome is a thrombotic microangiopathy characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Pathologically, it involves complement dysregulation leading to endothelial damage and microvascular thrombosis. Histological findings include glomerular capillary thrombosis and arteriolar thickening. It is classified under complement-mediated thrombotic microangiopathies and is distinct from typical HUS associated with Shiga toxin. Epidemiologically, it is a rare condition with an estimated prevalence of 1 in 500,000. The disease course can be chronic and relapsing, requiring long-term management strategies.
Atypical hemolytic uremic syndrome Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Hemolytic anemia manifests as fatigue, pallor, and shortness of breath due to the rapid destruction of red blood cells. The biological mechanism involves the formation of microthrombi in small blood vessels, leading to mechanical hemolysis. Over time, this can progress to severe anemia requiring blood transfusions. It affects daily life by causing significant fatigue and weakness, and management includes addressing the underlying cause and supportive care.
Thrombocytopenia presents with easy bruising, petechiae, and an increased risk of bleeding. It is caused by the consumption of platelets in the formation of microthrombi. As the condition progresses, platelet counts can drop to critically low levels, increasing the risk of spontaneous bleeding. Daily life is affected by the need to avoid activities that could cause injury, and treatment may include platelet transfusions and medications to reduce platelet destruction.
Acute kidney injury manifests as reduced urine output, fluid retention, and elevated blood pressure. The biological mechanism involves damage to the renal microvasculature due to microthrombi, leading to impaired kidney function. Over time, this can progress to chronic kidney disease if not managed effectively. It affects daily life by necessitating dietary restrictions and potential dialysis, with management focusing on controlling blood pressure and addressing the underlying cause.
Common
Hypertension in atypical hemolytic uremic syndrome presents as elevated blood pressure readings. It is caused by renal impairment and fluid overload due to reduced kidney function. If untreated, it can lead to further cardiovascular complications and exacerbate kidney damage. Management includes antihypertensive medications and lifestyle modifications to control blood pressure.
Neurological symptoms can include headache, confusion, and seizures. These occur due to microvascular damage in the brain and potential hypertensive encephalopathy. Over time, severe cases can lead to long-term neurological deficits. Daily life is affected by the need for close monitoring and potential interventions such as anticonvulsants and blood pressure control.
Fatigue is a common symptom, presenting as persistent tiredness and lack of energy. It is primarily due to anemia and the body's increased metabolic demands in response to the disease. Over time, fatigue can become debilitating, affecting physical and mental health. Management includes treating the underlying anemia and ensuring adequate rest and nutrition.
Less Common
Gastrointestinal symptoms may include nausea, vomiting, and abdominal pain. These symptoms are caused by microvascular damage and ischemia in the gastrointestinal tract. Over time, they can lead to malnutrition and weight loss if not addressed. Management involves supportive care and addressing the underlying microvascular damage.
Pulmonary edema presents as difficulty breathing, coughing, and reduced oxygen saturation. It is caused by fluid overload due to impaired kidney function and heart failure. If untreated, it can lead to respiratory distress and require hospitalization. Management includes diuretics to remove excess fluid and oxygen therapy to support breathing.
What Causes Atypical hemolytic uremic syndrome?
Atypical hemolytic uremic syndrome (aHUS) is primarily caused by mutations in genes regulating the complement system, such as CFH, CFI, MCP (CD46), C3, and CFB, located on chromosomes 1q31, 4q25, 1q32, 19p13, and 6p21, respectively. These genes encode proteins that are crucial for controlling the activation of the complement system, which is part of the immune response. Mutations in these genes can lead to a loss of function or gain of function, resulting in uncontrolled complement activation. This dysregulation causes excessive complement deposition on endothelial cells, leading to cell damage and microangiopathy. The dysfunction of endothelial cells disrupts normal blood flow and causes platelet activation and aggregation. This cascade results in thrombotic microangiopathy, characterized by hemolysis, thrombocytopenia, and renal impairment. The immune response is further amplified by the release of pro-inflammatory cytokines, contributing to systemic inflammation. Neuroinflammation may occur due to complement-mediated damage to the blood-brain barrier, leading to neurological symptoms. Degeneration of white matter structures can result from chronic inflammation and microvascular injury. Symptoms appear in a specific pattern due to the varying susceptibility of organs to complement-mediated damage, with kidneys being particularly vulnerable. Disease severity varies among patients due to genetic heterogeneity, environmental factors, and additional genetic modifiers. Some individuals may have protective genetic variants that mitigate disease severity. Conversely, others may have additional mutations that exacerbate the condition. The interplay between genetic predisposition and environmental triggers determines the clinical presentation and progression of aHUS.
How is Atypical hemolytic uremic syndrome Diagnosed?
Typical age of diagnosis: Atypical hemolytic uremic syndrome (aHUS) is typically diagnosed in childhood, though it can occur at any age. Diagnosis often follows an acute episode of hemolytic anemia, thrombocytopenia, and renal impairment. Early recognition is crucial to prevent irreversible kidney damage. Family history and genetic predisposition play significant roles in the diagnostic process.
Clinicians look for signs of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. A detailed medical history is taken to identify any preceding infections or familial patterns. Physical examination may reveal pallor, petechiae, or signs of renal impairment such as edema. This step helps differentiate aHUS from other thrombotic microangiopathies and guides further testing.
Renal ultrasound is commonly used to assess kidney size and structure. Abnormalities such as enlarged kidneys or increased echogenicity may be visible, supporting the diagnosis of renal involvement. Imaging helps confirm the presence of renal impairment and excludes other causes of acute kidney injury. It also aids in evaluating the extent of renal damage and planning further management.
Specific tests include complete blood count, lactate dehydrogenase, haptoglobin, and serum creatinine. Biomarkers like low haptoglobin and elevated LDH indicate hemolysis, while elevated creatinine reflects renal impairment. Abnormal results such as thrombocytopenia and hemolytic anemia are characteristic of aHUS. These findings guide the decision to pursue further genetic testing and initiate treatment.
Genes such as CFH, CFI, MCP, and C3 are sequenced to identify mutations. Mutations in these complement regulatory genes are commonly found in aHUS patients. Positive genetic results confirm the diagnosis and facilitate risk assessment for family members. They also inform genetic counseling and guide long-term management strategies.
Atypical hemolytic uremic syndrome Treatment Options
Eculizumab is a monoclonal antibody that inhibits the complement protein C5. It prevents the formation of the membrane attack complex, reducing hemolysis and renal damage. Clinical trials have shown significant improvement in renal function and hematological parameters with its use. However, it requires lifelong administration and carries a risk of serious infections, particularly meningococcal disease. Regular monitoring and vaccination are essential to mitigate these risks.
Techniques include exercises to improve cardiovascular fitness and muscle strength. The therapeutic goals are to enhance overall physical function and quality of life. Sessions are typically conducted 2-3 times per week, lasting about 30-45 minutes each. Measurable outcomes include improved exercise tolerance and reduced fatigue. Long-term benefits include better management of renal disease and reduced cardiovascular risk.
Indicated for patients with end-stage renal disease due to aHUS. The procedure involves replacing the damaged kidney with a healthy donor kidney. Expected benefits include improved renal function and quality of life. Surgical risks include rejection and infection, necessitating immunosuppressive therapy. Post-operative care involves regular monitoring of kidney function and adherence to immunosuppressive regimens.
The team includes nephrologists, hematologists, dietitians, and social workers. Interventions focus on managing symptoms, nutritional support, and psychological counseling. Psychosocial support strategies involve counseling and support groups for patients and families. Family education on disease management and treatment adherence is crucial. Long-term monitoring includes regular follow-ups to assess disease progression and treatment efficacy.
When to See a Doctor for Atypical hemolytic uremic syndrome
- Severe abdominal pain — this could indicate a serious complication such as intestinal ischemia.
- Sudden decrease in urine output — may suggest acute kidney injury requiring immediate medical attention.
- Unexplained bruising or bleeding — could be a sign of severe thrombocytopenia, necessitating urgent evaluation.
- Persistent high blood pressure — can lead to further kidney damage if not managed properly, consult your doctor.
- Fatigue and pallor — may indicate anemia, which requires medical assessment and possible treatment.
- Swelling in legs or feet — could be a sign of fluid retention, important to monitor and discuss with a healthcare provider.
- Mild headache — monitor for changes in severity or frequency, and maintain hydration.
- Occasional nausea — keep track of triggers and frequency, and ensure adequate nutrition.
Atypical hemolytic uremic syndrome — Frequently Asked Questions
Is this condition hereditary?
Atypical hemolytic uremic syndrome (aHUS) can be hereditary, often following an autosomal dominant pattern. The probability of passing it to children is 50% if one parent carries the mutation. De novo mutations can occur, meaning the condition can appear without a family history. Carriers may not show symptoms but can still pass the mutation to offspring. Genetic counseling is recommended for affected families to understand risks and implications.
What is the life expectancy for someone with this condition?
Life expectancy varies depending on age of onset and response to treatment. Early diagnosis and treatment improve outcomes significantly. Mortality is often due to renal failure or complications from hypertension. Eculizumab, a complement inhibitor, has improved survival rates. Realistic expectations include managing chronic symptoms and potential relapses.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves clinical evaluation, laboratory tests, and genetic testing. It typically takes weeks to months from first symptoms to diagnosis. Nephrologists and hematologists are often consulted. Delays occur due to symptom overlap with other conditions. Confirmation is through genetic testing and ruling out other causes of hemolytic uremic syndrome.
Are there any new treatments or clinical trials available?
Research is ongoing, with complement inhibitors like ravulizumab showing promise. Gene therapy is being explored as a potential future treatment. Clinical trials can be found on ClinicalTrials.gov by searching 'atypical hemolytic uremic syndrome'. Discussing trial eligibility with your doctor is crucial. New treatments may become available in the next few years.
How does this condition affect daily life and activities?
aHUS can impact mobility due to fatigue and joint pain. Educational adjustments may be needed for children due to frequent medical appointments. Social and emotional challenges include coping with chronic illness and potential isolation. Family burden is significant due to caregiving responsibilities. Supportive therapies and community resources can aid in adaptation.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment.
Raina R, Krishnappa V, Blaha T et al. · Ther Apher Dial · 2019 · PMID: 30294946
- 2.Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy.
Java A · Hematology Am Soc Hematol Educ Program · 2024 · PMID: 39644051
- 3.Atypical hemolytic uremic syndrome: Consensus of diagnosis and treatment in Taiwan.
Tseng MH, Lin SH, Tsai JD et al. · J Formos Med Assoc · 2023 · PMID: 36323601
- 4.Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
Goodship TH, Cook HT, Fakhouri F et al. · Kidney Int · 2017 · PMID: 27989322
- 5.How I diagnose and treat atypical hemolytic uremic syndrome.
Fakhouri F, Schwotzer N, Frémeaux-Bacchi V · Blood · 2023 · PMID: 36322940
- 6.Atypical Hemolytic Uremic Syndrome.
Dixon BP, Gruppo RA · Pediatr Clin North Am · 2018 · PMID: 29803280
- 7.Atypical Hemolytic Uremic Syndrome: Beyond Hemolysis and Uremia.
Tsai HM · Am J Med · 2019 · PMID: 30145224
- 8.An international consensus approach to the management of atypical hemolytic uremic syndrome in children.
Loirat C, Fakhouri F, Ariceta G et al. · Pediatr Nephrol · 2016 · PMID: 25859752
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-12